These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 35443108)

  • 61. Ivosidenib: an investigational drug for the treatment of biliary tract cancers.
    Angelakas A; Lamarca A; Hubner RA; McNamara MG; Valle JW
    Expert Opin Investig Drugs; 2021 Apr; 30(4):301-307. PubMed ID: 33683991
    [No Abstract]   [Full Text] [Related]  

  • 62. FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation.
    Casak SJ; Pradhan S; Fashoyin-Aje LA; Ren Y; Shen YL; Xu Y; Chow ECY; Xiong Y; Zirklelbach JF; Liu J; Charlab R; Pierce WF; Fesenko N; Beaver JA; Pazdur R; Kluetz PG; Lemery SJ
    Clin Cancer Res; 2022 Jul; 28(13):2733-2737. PubMed ID: 35259259
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma.
    Corrigan L; Lowery M
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):475-481. PubMed ID: 33836133
    [No Abstract]   [Full Text] [Related]  

  • 64. Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.
    Norsworthy KJ; Mulkey F; Scott EC; Ward AF; Przepiorka D; Charlab R; Dorff SE; Deisseroth A; Kazandjian D; Sridhara R; Beaver JA; Farrell AT; de Claro RA; Pazdur R
    Clin Cancer Res; 2020 Aug; 26(16):4280-4288. PubMed ID: 32393603
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells.
    Gruber E; So J; Lewis AC; Franich R; Cole R; Martelotto LG; Rogers AJ; Vidacs E; Fraser P; Stanley K; Jones L; Trigos A; Thio N; Li J; Nicolay B; Daigle S; Tron AE; Hyer ML; Shortt J; Johnstone RW; Kats LM
    Cell Rep; 2022 Aug; 40(7):111182. PubMed ID: 35977494
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.
    DiNardo CD; Stein EM; Pigneux A; Altman JK; Collins R; Erba HP; Watts JM; Uy GL; Winkler T; Wang H; Choe S; Liu H; Wu B; Kapsalis SM; Roboz GJ; de Botton S
    Leukemia; 2021 Nov; 35(11):3278-3281. PubMed ID: 33772143
    [No Abstract]   [Full Text] [Related]  

  • 67. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy.
    Wang ES; Montesinos P; Minden MD; Lee JH; Heuser M; Naoe T; Chou WC; Laribi K; Esteve J; Altman JK; Havelange V; Watson AM; Gambacorti-Passerini C; Patkowska E; Liu S; Wu R; Philipose N; Hill JE; Gill SC; Rich ES; Tiu RV
    Blood; 2022 Oct; 140(17):1845-1857. PubMed ID: 35917453
    [TBL] [Abstract][Full Text] [Related]  

  • 68. PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction.
    Bolleddula J; Ke A; Yang H; Prakash C
    CPT Pharmacometrics Syst Pharmacol; 2021 Jun; 10(6):577-588. PubMed ID: 33822485
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Molecular Complete Remission Following Ivosidenib in a Patient With an Acute Undifferentiated Leukemia.
    Patel SH; Vasu S; Guo L; Lemaster O; Byrd JC; Walker A
    J Natl Compr Canc Netw; 2020 Jan; 18(1):6-10. PubMed ID: 31910380
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects.
    Dai D; Yang H; Nabhan S; Liu H; Hickman D; Liu G; Zacher J; Vutikullird A; Prakash C; Agresta S; Bowden C; Fan B
    Eur J Clin Pharmacol; 2019 Aug; 75(8):1099-1108. PubMed ID: 31011758
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.
    Ravandi F; Ritchie EK; Sayar H; Lancet JE; Craig MD; Vey N; Strickland SA; Schiller GJ; Jabbour E; Erba HP; Pigneux A; Horst HA; Recher C; Klimek VM; Cortes J; Roboz GJ; Odenike O; Thomas X; Havelange V; Maertens J; Derigs HG; Heuser M; Damon L; Powell BL; Gaidano G; Carella AM; Wei A; Hogge D; Craig AR; Fox JA; Ward R; Smith JA; Acton G; Mehta C; Stuart RK; Kantarjian HM
    Lancet Oncol; 2015 Sep; 16(9):1025-1036. PubMed ID: 26234174
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Ivosidenib Deemed Safe, Effective in AML.
    Cancer Discov; 2018 Aug; 8(8):OF1. PubMed ID: 29934313
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.
    Mellinghoff IK; Lu M; Wen PY; Taylor JW; Maher EA; Arrillaga-Romany I; Peters KB; Ellingson BM; Rosenblum MK; Chun S; Le K; Tassinari A; Choe S; Toubouti Y; Schoenfeld S; Pandya SS; Hassan I; Steelman L; Clarke JL; Cloughesy TF
    Nat Med; 2023 Mar; 29(3):615-622. PubMed ID: 36823302
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow-up from a phase 1b study.
    Pollyea DA; Pratz K; Letai A; Jonas BA; Wei AH; Pullarkat V; Konopleva M; Thirman MJ; Arellano M; Becker PS; Chyla B; Hong WJ; Jiang Q; Potluri J; DiNardo CD
    Am J Hematol; 2021 Feb; 96(2):208-217. PubMed ID: 33119898
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effects of azacitidine in 93 patients with
    Willekens C; Rahme R; Duchmann M; Vidal V; Saada V; Broutin S; Delahousse J; Renneville A; Marceau A; Clappier E; Uzunov M; Rossignol J; Pascal L; Simon L; Micol JB; Pasquier F; Raffoux E; Preudhomme C; Quivoron C; Itzykson R; Penard-Lacronique V; Paci A; Fenaux P; Attar EC; Frattini M; Braun T; Ades L; De Botton S
    Leuk Lymphoma; 2021 Feb; 62(2):438-445. PubMed ID: 33043739
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Ivosidenib, an IDH1 inhibitor, in a patient with recurrent,
    Tejera D; Kushnirsky M; Gultekin SH; Lu M; Steelman L; de la Fuente MI
    CNS Oncol; 2020 Sep; 9(3):CNS62. PubMed ID: 32716208
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date.
    Uson Junior PLS; Borad MJ
    Cancer Manag Res; 2023; 15():1025-1031. PubMed ID: 37746315
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Assessing acquired resistance to IDH1 inhibitor therapy by full-exon
    Oltvai ZN; Harley SE; Koes D; Michel S; Warlick ED; Nelson AC; Yohe S; Mroz P
    Cold Spring Harb Mol Case Stud; 2021 Apr; 7(2):. PubMed ID: 33832922
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy.
    Griffin PT; Komrokji RS; De Castro CM; Rizzieri DA; Melchert M; List AF; Lancet JE
    Am J Hematol; 2015 Sep; 90(9):796-9. PubMed ID: 26089240
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials.
    Aiman W; Ali MA; Basit MA; Omar Z; Suleman M; Hassan M; Jamil T; Anwar MS; Shafique Z; Dhanesar G; Faisal MS; Akerman MJ; Maroules M; Anwer F
    Leuk Res; 2023 Jun; 129():107077. PubMed ID: 37100025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.